ClinicalTrials.gg
RecruitingNCT06304571Updated May 6, 2025

A Study of HC006 in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of HC006 in Advanced Solid Tumor, sponsored by HC Biopharma Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by HC Biopharma Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid tumor malignancies. This study is a first-in-human (FIH) study of HC006 in subjects with advanced solid tumors.

Read the detailed description

HC006, a novel therapeutic monoclonal antibody that specifically binds to human C-C motif chemokine receptor 8 (CCR8) and is designed to selectively deplete tumor-infiltrating T regulatory cells (Tregs) with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). In mouse tumor models, HC006 has demonstrated excellent antitumor activity and safety profile. This first-in-human (FIH) study will be conducted in two parts. In the Dose-Escalation part, testing will be done on up to 31 subjects to determine the maximum tolerated dose (MTD) and the recommended dose (RD). In the Dose-expansion part, we will evaluate the safety and efficacy of the recommended dose of HC006 in the treatment of advanced solid tumor subjects without standard therapy.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

HC Biopharma Inc. is the lead sponsor of 9 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have confirmed and documented diagnosis of locally advanced unresectable or advanced solid tumor that is to standard treatment, or intolerant to standard treatment, or for which no standard treatment exists.
  • At least one for expansion cohorts per (RECIST) v1.1(dose escalation only requires at least one assessable lesion)
  • Agree to provide archived or fresh tumor tissue samples of primary or metastatic lesions for expansion cohorts.
  • ≥12 weeks
  • (ECOG) performance status of 0-1
  • Have adequate organ function as described in the protocol.
  • Agree to adopt effective measures.

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to CCR8 inhibitor or to any ingredient of the study drug.
  • Treatment with any systemic anti-cancer treatment within 4 weeks before first dose of study drug.
  • Use of any within 28 days.
  • With primary central nervous system (CNS) tumors or unstable .
  • Have active or history of disease or immunodeficiency disease.
  • With active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
  • With any mental or cognitive impairment that may limit their understanding, implementation.
  • Major surgery within 4 weeks of study drug administration.
  • Have uncontrolled or severe illness, including but not limited to severe cardiovascular disease, interstitial lung disease or non-infectious pneumonia, or uncontrollable clinical third luminal effusion.
  • Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of v5.0.
  • History of other within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma.
  • Women who are pregnant or breastfeeding.
  • Other protocol defined exclusion criteria may apply.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    HC006 Dose Escalation

    Drug: HC006

  • Experimental
    HC006 Dose Expansion

    Drug: HC006

Interventions

  • DrugHC006

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with Dose Limiting Toxicities(DLTs)as assessed by protocol

    Incidence of Dose Limiting Toxicities(DLTs)

    Time frame: up to 24 months

  2. Number of participants with adverse events(AEs) as assessed by CTCAE v5.0

    Incidence of adverse events(AEs)

    Time frame: up to 24 months

  3. Number of participants with Serious adverse events(SAEs)as assessed by CTCAE v5.0

    Incidence of Serious adverse events(SAEs)

    Time frame: up to 24 months

  4. Percentage of Participants Experiencing Laboratory and ECG Abnormalities According to the NCI CTCAE v5.0

    Percentage of Participants Experiencing Laboratory and ECG Abnormalities According to the NCI CTCAE v5.0

    Time frame: up to 24 months

Secondary outcomes

  1. Pharmacokinetic (PK) Parameter:Maximum serum concentration (Cmax)

    Maximum serum concentration (Cmax)

    Time frame: up to 24 months

  2. PK Parameter:Time to reach Cmax (Tmax)

    Time to reach Cmax (Tmax)

    Time frame: up to 24 months

  3. PK Parameter:Area Under the Concentration-time Curve (AUC)

    Area Under the Concentration-time Curve (AUC)

    Time frame: up to 24 months

  4. Immunogenicity

    Incidence of anti-drug antibodies (ADAs) to HC006

    Time frame: up to 24 months

  5. Objective Response Rate (ORR) per RECIST 1.1

    The sum of the proportions of subjects who achieved CR or PR in imaging evaluation as assessed by the investigator based on RECIST1.1 criteria.

    Time frame: up to 24 months

  6. progression-Free Survival (PFS) per RECIST 1.1

    Time from first dose of the investigational drug to PD or death from any cause.

    Time frame: up to 24 months

  7. Overall Survival (OS)

    Time from first dose of the investigational drug to death from any cause.

    Time frame: up to 24 months

  8. Disease Control Rate (DCR) per RECIST 1.1

    The sum of proportions of subjects who achieved CR, PR, and SD in imaging evaluation.

    Time frame: up to 24 months

  9. Duration of response (DOR) per RECIST 1.1

    Time from the first evaluated CR or PR until PD or death from any cause.

    Time frame: up to 24 months

  10. Time to progression (TTP) per RECIST 1.1

    Time from first dose of the investigational drug to the tumor evaluation of PD.

    Time frame: up to 24 months

  11. Time To Response (TTR) per RECIST 1.1

    Time from first dose of the investigational drug to the first tumor evaluation of CR or PR.

    Time frame: up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Mar 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2024
First posted
Mar 12, 2024
StartActual
Feb 27, 2024
Primary completionEst.
Mar 15, 2026
CompletionEst.
Jul 16, 2026
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06304571
Lead sponsor
HC Biopharma Inc.
Responsible party
Sponsor
First posted
Mar 12, 2024
Start date
Feb 27, 2024
Primary completion
Mar 15, 2026 (estimated)
Completion
Jul 16, 2026 (estimated)
Last update
May 6, 2025

Study contacts

langxi Zhang, PhD
Contact
langxi.zhang@btyy.com
00-86-021-50433368

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion